JMP Securities Reiterates a Buy Rating on Steris (STE)

JMP Securities analyst David Turkaly reiterated a Buy rating on Steris (STEResearch Report) today and set a price target of $270.00. The company’s shares closed last Thursday at $230.71.

According to, Turkaly is a 2-star analyst with an average return of 0.6% and a 42.3% success rate. Turkaly covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Integra Lifesciences, and OrthoPediatrics.

Steris has an analyst consensus of Strong Buy, with a price target consensus of $256.00, an 11.3% upside from current levels. In a report issued on May 12, Wolfe Research also maintained a Buy rating on the stock with a $250.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $255.93 and a one-year low of $188.10. Currently, Steris has an average volume of 476.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

STERIS Plc (Ireland) engages in the manufacture of medical and surgical equipment. The company was founded on December 22, 2016 and is headquartered in Dublin, Ireland.

Read More on STE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed